AgeX Therapeutics (AGE) Peer Comparison

$11.10

$-1.50 (-11.90%)

As on 26-Mar-2024 20:00EDT

Market cap

$28 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

5.1

Div. Yield

0 %

Edit

	AgeX Therapeutics (AGE)	Cymabay Therapeu (CBAY)
Market cap ($ Mln)	28	3,728
Revenue ($ Mln)	0	31
Net Profit ($ Mln)	-14.80	-105.37
Net Margin (%)	-14,191.67	-332.64
RoE (%)	252.12	-64.17
Price to Earnings	--	--
Price-To-Book	5.08	12.76

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	AgeX Therapeutics (AGE)	Cymabay Therapeu (CBAY)
Operating Revenue	0.14	31.07
Cost of Revenue	0.17	0.68
Gross Profit	-0.03	30.39
Operating Expenses	9.93	132.07
Operating Profit (EBIT)	-9.96	-101.68
Other Income	--	--
Profit before Tax	-14.81	-105.37
Provision for Tax	-0.01	--
Profit after Tax (Net Income)	-14.80	-105.37
Minority Interest	--	--
Consolidated Profit	--	--

Liabilities ($ Mln)

	AgeX Therapeutics (AGE)	Cymabay Therapeu (CBAY)
Shareholder's Funds	5.47	292.26
Minority Interest	--	--
Non-Current Liabilities	0.69	105.59
Current Liabilities	5.91	36.84
Total Liabilities	11.97	434.69

Assets ($ Mln)

	AgeX Therapeutics (AGE)	Cymabay Therapeu (CBAY)
Non-Current Assets	11.21	30.88
Current Assets	0.75	403.80
Total Assets	11.97	434.69
Total Debt*	4.37	114.49
Net Current Assets	-5.16	366.96

Cashflow ($ Mln)

	AgeX Therapeutics (AGE)	Cymabay Therapeu (CBAY)
Cash From Operating Activities	-7.80	-72.53
Cash Flow from Investing Activities	--	--
Cash from Financing Activities	17.50	345.77
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	AgeX Therapeutics (AGE)	Cymabay Therapeu (CBAY)
ROCE (%)	-275.51	-39.48
ROE (%)	252.12	-64.17
ROA (%)	-194.70	-36.55
EBIT Margin (%)	--	--
Net Margin (%)	-10,424.65	-339.10
Cash Profit Margin (%)	--	--

Growth Ratios

	AgeX Therapeutics (AGE)	Cymabay Therapeu (CBAY)
Revenue Growth (%)	3.18	0.00
EBIT Growth (%)	--	--
Net Profit Growth (%)	-38.68	11.37
EPS Growth (%)	-0.39	0.26
Book Value Growth (%)	--	--

Valuation Ratios

	AgeX Therapeutics (AGE)	Cymabay Therapeu (CBAY)
Price / Earnings	-0.03	-23.76
Price / Book Value	0.08	8.57
Dividend Yield (%)	--	--
EV/EBITDA	-0.45	-22.02
Market Cap ($ Cr)	--	--

Solvency Ratios

	AgeX Therapeutics (AGE)	Cymabay Therapeu (CBAY)
Debt to Equity	0.80	0.39
Short term debt to equity ratio	0.67	0.03
Current Ratio	0.13	10.96
Quick Ratio	--	--
Interest Coverage	-2.03	-5.37

Operating Efficiency Ratios

	AgeX Therapeutics (AGE)	Cymabay Therapeu (CBAY)
Debtors to sales (%)	40.14	--
Asset Turnover	0.02	0.11
Receivable days	78.45	34.19
Inventory Days	--	--
Payable days	2,613.35	1,320.48
Cash Conversion Cycle	--	--

Annual
Quarterly